June 28 is International Neonatal Screening Day. We join with the global community of advocates who support this important safeguard. “Neonatal screening isn’t just a medical test — it is a public health intervention that, when implemented universally, has the power to save lives, improve quality of life and reduce long-term health costs,” said Johan Prevot, Executive Director of the International Patient Organisation for Primary Immunodeficiencies \(IPOPI\). #neonatalscreening #internationalneonatalscreeninday #CSL
World Sickle Cell Day 2025
People who live with sickle cell disease cope with a debilitating condition that alters the course of their lives.
World Sickle Cell Day, June 19, is a day to raise awareness about the need for patient-focused research and innovation.
CSL's 2025 Half Year Financial Results Click here for Full Information including Webcast Recording → | Would you like to read our 2024 Annual Report? Click here to view or download the Annual Report →
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL Behring. Leading the Way in Treating Rare and Serious Diseases.
CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
More About CSL Behring
CSL Seqirus. Global Vaccine Leader.
Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.
More About CSL Seqirus
CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.
The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.
More About CSL ViforVita: Original Stories
'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.
Careers at CSL
We are committed to helping employees fulfill their career aspirations while working in a values-based culture. Are you next?
Pictured: A CSL employee in Bern, Switzerland
30 Jun
We had the great privilege of welcoming Stéphanie Sénéchal, President of AIRG Switzerland, to Villars-sur-Glâne, where she shared her inspiring story as a patient living with a rare kidney disease, along with her exceptional dedication to her association. ✨ Highlights: 💡 A moving and inspiring testimony that reminded us of the vital importance of listening, encouragement, and collaboration to better understand the daily realities faced by those affected. 💬 Meaningful and enriching exchanges that raised awareness of the challenges rare kidney diseases present and the difficult access to innovative medicines, while strengthening our commitment to this cause. 🙌 A heartfelt thank you to Stéphanie Sénéchal for her presence, her presentation, and the valuable exchange we shared! 📢 Together, let’s keep raising awareness and driving progress in the field of rare kidney diseases. Every voice, every action, every person counts! Find out more about AIRG Switzerland https://bit.ly/44q3thI #CSLVifor #patientfocus #rarediseases
27 Jun
25 Jun
Patient care extends beyond developing therapies. We proudly partner with patient organizations and advocacy groups to ensure that individuals living with rare and serious conditions receive the education, support and care they need. #RareDiseaseAdvocacy #PatientFocus Learn more about our patient support initiatives: https://bit.ly/4lmIRO0
24 Jun
CSL is excited to announce our new partnership with NYBC Ventures to identify and evaluate cutting-edge early-stage biotech opportunities. This collaboration strengthens our connection to North America’s vibrant innovation ecosystem and reinforces our commitment to nurturing biotech breakthroughs.
20 Jun
🎉 Celebrating 25 years of CSL Behring Bern! For a quarter of a century, our Bern site has played a pivotal role in CSL’s global network — delivering life-saving therapies, driving innovation, and playing a vital role in the City of Bern and beyond. We were honored to mark this milestone with CEO Paul McKenzie, members of the Global Leadership Group, the Board of Directors, and Chairman Dr. Brian McNamee, whose reflections reminded us how far we’ve come — from the integration of ZLB Bioplasma and Aventis Behring into ZLB Behring AG to becoming a cornerstone of CSL’s success. Thank you to all employees past and present, our long-serving team members, who have helped shape this legacy — and continue to build its future. https://bit.ly/4ncrGk6 #CSLBehring #Bern25Years #Impact #Innovation
18 Jun
June 19 is #WorldSickleCellDay – a good day to learn about this group of debilitating genetic conditions that impact approximately 8 million people worldwide, and about the efforts to develop much needed, innovative treatments for patients and the wider community. CSL is proud to contribute to this important work and will imminently begin enrolment in a Stage 2/3 trial. https://bit.ly/45pK4j1
18 Jun
Innovation meets convenience with our first homegrown recombinant monoclonal antibody to gain approval by the FDA, a significant milestone in our commitment to advancing hereditary angioedema \(HAE\) treatment. With once-monthly dosing via an autoinjector, it offers a new option that may help patients manage their condition. We’re proud to bring this innovation to the HAE community around the world and continue our legacy of delivering breakthrough therapies for rare diseases. https://bit.ly/40buGTI #HAE #CSL #Biotech #Pharma #FDAApproval #HereditaryAngioedema
2 Jun
Happy Pride Month! 🌈 Today and every day, we celebrate love, identity, and the power of living authentically. Here's to a world where everyone can shine as their true selves. https://bit.ly/43rcIPr #CSL #Pride #LoveIsLove
17 Jun
CSL is proud to have sponsored hackathons at Drexel University, North Carolina State University and Rochester Institute of Technology. These events brought together talented students to develop creative solutions to real-world business challenges. Hackathons are a fantastic way to foster innovation and collaboration. Our involvement included mentoring participants, judging competitions, and staffing CSL tables to discuss technology and plasma donation. These hackathons help us connect with future leaders and reinforce CSL’s culture of collaboration and innovation. We look forward to continuing our support for STEM education and community engagement. #CSL #Hackathon #STEM #Innovation #CommunityEngagement #PromisingFutures
17 Jun
The U.S. FDA has approved the only once-monthly treatment targeting factor XIIa for prophylactic use to prevent attacks of hereditary angioedema \(HAE\). This milestone, along with recent approvals in multiple countries around the world, reinforces our global commitment to delivering transformational innovations to HAE patients, a community we have proudly supported for over four decades. Read more: https://bit.ly/3SR5uy5. #HAE #CSL #Biotech #Pharma #FDAApproval #HereditaryAngioedema
